When you join OncoSHARE, you become a member of an active network gathering together more than 13,000 patients and oncologists.
Regardless of whether the information concerns patient health or payment, we take every precaution to ensure your security. OncoSHARE is used by oncologists to order our solutions, to display interactive analysis reports and to connect health care professionals to each other and to our team of experts.
In a simple, interactive manner, OncoSHARE will guide you in your selection of the most appropriate treatment options based on the unique signature of your patient’s tumour.
Ordering our biomarker tests is very simple through OncoSHARE, a highly secured platform.
Once we receive your order, we will send you a DHL shipment kit with a prepaid return air waybill and all the necessary material and documents for the shipping back to OncoDNA. Within a few days, we will get the tumour or blood sample and start the analysis.
A comprehensive and integrated report will be available after 7 to 10 days (depending on the test ordered). In a simple and interactive manner, it will guide you in selecting the most appropriate treatments based on the unique signature of the tumour.
Key findings from the different tests, simplified pathway analyses and treatment recommendations based on molecular and clinical evidence.
List of treatments associated with potential clinical benefit, potential lack of clinical benefit, undetermined clinical benefit and toxicity for each patient. Moreover, we provide you with the trade names, therapeutic classes, official indications and the approval status per cancer type.
List of the clinical trials associated with certain molecular features of the patient's tumour.
List of all references used in the report and related to the patient’s molecular profile.
• High definition image of the tumour sample
• Clinical form with patient clinical data
• Cancer type and stage
• Complete list of variants and their biological and therapeutical impact
• List of genes sequenced
• MSI (microsatellite instability)
• TMB (tumour mutational burden)
• Alpha list: Biomarkers associated with FDA and/or EMA approved drugs with pharmacogenomic information on their labels, as well as variants associated with clinical resistance or sensitivity to FDA/EMA approved drugs
• Immunohistochemistry tests
• Unusual splicing and methylation
• Translocations or fusions
The immunogram shows the potential response of each patient to immunotherapy. It is created from (1) the percentage of PD-L1-positive tumor cells, (2) the percentage of infiltrated CD8+ T cells, (3) the level of tumour mutational burden, (4) the microsatellite stability status of the tumour, and (5) the presence of mutations associated with either sensitivity or resistance to immunotherapy